Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Terns Pharmaceuticals (DE:430)
BERLIN:430
RESEARCH TOOLSreports
Terns Pharmaceuticals (430) Stock Price & Analysis
0 Followers
430 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€3.10 - €12.24
Previous Close€4.52
Volume0.00
Average Volume (3M)N/A
Market Cap
€296.71M
Enterprise Value€48.44M
Total Cash (Recent Filing)$266.60M
Total Debt (Recent Filing)$770.00K
Price to Earnings (P/E)N/A
Beta-1.03
Next Earnings
May 13, 2024EPS Estimate
-€0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
€13.94Price Target Upside208.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Terns Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressTERN is developing TERN-701, an allosteric BCR-ABL1 inhibitor for the treatment of CML, with potential to be similar to, if not better than, Novartis' Scemblix/asciminib.
Financial HealthThe company's cash runway remains sufficient to sustain operations into 2026, allowing them to pursue their strategic goals without immediate financial pressure.
Market OpportunityEli Lilly announced highly anticipated, positive top-line data from SURMOUNT-OSA Study, which could indicate broader use and benefits for GLP-1 class drugs, enhancing the commercial opportunity for TERN's oral GLP-1 program.
Bears Say
Clinical Trial OutcomesEnliven Therapeutics presented initial positive Phase 1 data for ELVN-001, introducing a new potential competitor in the CML treatment space.
Financial PerformanceTERN reported a net loss for the year, which may raise concerns about long-term profitability.
Operational ChallengesTERN likely needs a partner to develop TERN-501, indicating a potential challenge in progressing the NASH program independently.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
10.29% Other Institutional Investors
89.71% Public Companies and
Individual Investors
430 FAQ
What was Terns Pharmaceuticals’s price range in the past 12 months?
Terns Pharmaceuticals lowest stock price was €3.10 and its highest was €12.24 in the past 12 months.
What is Terns Pharmaceuticals’s market cap?
Currently, no data Available
When is Terns Pharmaceuticals’s upcoming earnings report date?
Terns Pharmaceuticals’s upcoming earnings report date is May 13, 2024 which is in 14 days.
How were Terns Pharmaceuticals’s earnings last quarter?
Terns Pharmaceuticals released its earnings results on Mar 14, 2024. The company reported -€0.271 earnings per share for the quarter, beating the consensus estimate of -€0.274 by €0.003.
Is Terns Pharmaceuticals overvalued?
According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued.
Does Terns Pharmaceuticals pay dividends?
Terns Pharmaceuticals does not currently pay dividends.
What is Terns Pharmaceuticals’s EPS estimate?
Terns Pharmaceuticals’s EPS estimate is -€0.32.
How many shares outstanding does Terns Pharmaceuticals have?
Currently, no data Available
What happened to Terns Pharmaceuticals’s price movement after its last earnings report?
Terns Pharmaceuticals reported an EPS of -€0.271 in its last earnings report, beating expectations of -€0.274. Following the earnings report the stock price went up 8.882%.
Which hedge fund is a major shareholder of Terns Pharmaceuticals?
Among the largest hedge funds holding Terns Pharmaceuticals’s share is Fairmount Funds Management Llc. It holds Terns Pharmaceuticals’s shares valued at 13M.
---
Terns Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€13.94 (208.42% Upside)
€13.94 (208.42% Upside)
Blogger Sentiment
Bullish
DE:430 Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.30%
12-Months-Change
Fundamentals
Return on Equity
-33.89%
Trailing 12-Months
Asset Growth
-6.45%
Trailing 12-Months
Company Description
Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
---
430 Stock 12 Months Forecast
Average Price Target
€13.94
▲(208.42% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Alnylam Pharma
―
Amicus
―
Arrowhead Pharmaceuticals
―
Terns Pharmaceuticals
―
Best Analysts Covering 430
1 Year
1 Year Success Rate
2/6 ratings generated profit
1 Year Average Return
+11.15%
reiterated a buy rating 2 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +11.15% per trade.
---